Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) (PASCE)
An Open Label Multicentric Phase II Study of Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)
Squamous Cell Carcinoma (SCC) is one of the most common malignancies in caucasian population. The effect of the immune system on the development of skin tumors has been demonstrated in transplant patients taking immunosuppressive agents (65 fold risk increase). It has been reported that activation of EGFR and RAS signaling pathways play an important role in disease progression maybe through downregulation of the immune system.
The investigators want to treat unresectable SCC patients with an antibody against EGFR (Vectibix®, panitumumab). This antibody induces tumor regression in metastatic colorectal cancer and has been approved as single agent for this indication.
The investigators want to measure the response rate but also analyze the modification of expression profile of some key proteins involved or supposed to be involved in the signaling pathways of EGFR and in the regulation of the immune system. Chemokines such as CCL27 have been shown to play a critical role in the skin-associated immune response by regulating T cell homing. Pivarcsi et al have reported that downregulation of CCL27 is mediated by activation of EGFR/RAS/MAPK signaling pathways.
연구 개요
상세 설명
This is an open-label, multicentric study of 17 patients with skin squamous cancer cell.
Eligible patients should not be suitable for immediate surgery. If they have only one tumor, it should be greater than 3 cm2 in order to allow multiple biopsies.
Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
Patients will be assessed at baseline, at week 6 and then every 12 weeks till progression. In addition to clinical examination, evaluation tools will include photography and CT-scan, MRI or PET-scan.
Skin and tumor biopsies will be performed during first cycle at baseline and at days 2, 4, 8, 43, 85. Blood collections for translational research will be done during first cycle at baseline and at days 2, 4, 8,15, 43, 85. Blood collection for hematology and chemistry assessment will be done each 4weeks.
Patients presenting with a stable disease or a tumor response at week 12 will be eligible for maintenance cycles consisting in an infusion of panitumumab every 2 weeks till progression.
연구 유형
등록 (예상)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Bruxelles, 벨기에, 1200
- 모병
- Cliniques Universitaires Saint-Luc Université Catholique de Louvain
-
연락하다:
- Baurain Jean-Francois, Md,PhD
- 전화번호: +32 2 7645427
- 이메일: jean-françois.baurain@uclouvain.be
-
연락하다:
- Duquenne Aline, MSc
- 전화번호: +32 2 764 5427
- 이메일: aline.duquenne@uclouvain.be
-
Mont Godinne, 벨기에, 5530
- 모병
- Cliniques Universitaires UCL
-
연락하다:
- Kerger Joseph, MD, PhD
- 전화번호: +32 81423328
-
Ottignies, 벨기에, 1340
- 모병
- Cliniques Saint-Pierre
-
연락하다:
- Duck Lionel, MD
- 전화번호: +32 10414953
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria
- Patient with histologically confirmed diagnosis of SCC.
- Patient must not be candidate to direct curative surgery.
- Tumor evaluation by photography with a ruler and CT-scan, MRI or PET-scan must be performed before enrollment.
- Age ≥ 18 years.
- Karnofsky Performance status (KPS) ≥70.
Normal laboratory values:
- Platelet count ≥100x103/μL
- Leucocyte count ≥ 3x103/μL
- Hemoglobin ≥ 9 g/dL
- ASAT and ALAT ≤ 2.5xUNL
- Serum creatinine ≤1.5xUNL
- Total bilirubin ≤ 1.5xUNL
- Magnesium ≥ Lower Normal Limit (LLN)
- Calcium ≥ Lower Normal Limit (LLN)
- Patient should agree to perform biopsies and blood collections for translational research.
- Signed informed consent from the patient or legal representative must be obtained.
Exclusion criteria
- Clinically significant cardiovascular disease (including cardiac insufficiency NYHA grade III and IV, unstable angina, arrythmia, myocardial infarction, symptomatic congestive heart failure)in the past 12 months before enrollment.
- History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan.
- No prior chemotherapy.
- Prior anti-EGFR therapy.
- Radiation within four weeks prior to trial entry.
- Subject pregnant or breastfeeding, or planning to become pregnant within 6 months after the end of treatment.
- Subject (male or female) not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months after the end of treatment.
- The patient has (or has had) previous or concomitant malignancies at other sites within last 5years, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: panitumumab
Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
|
Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Response Rate (ORR)
기간: via imaging every 12 weeks
|
To measure the efficacy of Panitumumab for SCC in terms of Overall Response Rate (ORR).
Overall Response Rate (ORR) is defined as the sum of complete and partial tumour responses seen, divided by the total number of evaluable patients.
|
via imaging every 12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
To assess the safety profile of panitumumab in SCC
기간: at each visit
|
Proportion of all adverse events will be reported.
CTC scale 3.0 will be used with the exception of skin- or nail-related toxicities, which must be graded using CTC version 3.0 with modifications (Appendix E).
Patients will be followed for safety until closure of study.
|
at each visit
|
|
Time to treatment failure (TTF)and Time to treatment progression TTP
기간: via imaging, every 12 weeks
|
Time to treatment failure (TTF) is defined as the time from date of first dose of study medication to first occurrence of any following event : documentation of objective tumor progression, toxicities requiring prematurely stop of treatment or death.
TTF will be calculated according to the Kaplan-Meier technique.
Time to Progression will also be calculated.
Subjects without evidence of progression at the end of follow up will be considered as censored.
|
via imaging, every 12 weeks
|
|
To measure the duration of response.
기간: via imaging, every 12 weeks
|
Duration of overall response will be measured according RECIST guidelines version 1.1 Duration of response is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded on study).
|
via imaging, every 12 weeks
|
|
To explore the gene expression profiles in SCC under panitumumab treatment (i.e CCL27, EGFR,…).
기간: Skin and tumor biopsies will be performed at baseline and at days 2, 4, 8, 43, 85. Blood will be collected at baseline and at days 2, 4, 8, 43, 85
|
Results will be presented as proportion of each expression type.
|
Skin and tumor biopsies will be performed at baseline and at days 2, 4, 8, 43, 85. Blood will be collected at baseline and at days 2, 4, 8, 43, 85
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Baurain Jean-Francois, Md,PhD, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- Luc 09-002
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
암종, 편평 세포에 대한 임상 시험
-
Taichung Veterans General Hospital완전한심장 독성 | 비소세포폐암 (MeSH 용어: Carcinoma, Non-Small-Cell Lung) | 의약품 관련 부작용 및 이상반응 (MeSH 용어) | Egfr 티로신 키나아제 억제제대만
-
Sandy SrinivasGlaxoSmithKline완전한방광암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전) | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성) | 방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능미국
-
Fondazione Policlinico Universitario Agostino Gemelli...모병상부 요로상피암 | 방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능이탈리아
-
Ankara UniversityFondazione IRCCS Istituto Nazionale dei Tumori, Milano아직 모집하지 않음방광(Urothelial, Transitional Cell) 암 전이성 또는 절제 불가능
-
Ciusss de L'Est de l'Île de MontréalStem Cell Network모병급성 백혈병, 고위험군 | 고위험 골수형성이상증후군 | Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor캐나다
-
Fondazione del Piemonte per l'Oncologia모병유방암 | 난소 암 | 대장암 | 흑색종(피부암) | 비소세포폐암 (MeSH 용어: Carcinoma, Non-Small-Cell Lung)이탈리아
-
Stanford UniversityNational Institutes of Health (NIH)빼는방광암 | 피부암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 절제 가능한 암(방광절제술 전)미국
-
Relmada Therapeutics, Inc.빼는요로상피암 방광 | 비뇨기과 암 | 요로상피암 재발성 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성)
-
Millennium Pharmaceuticals, Inc.완전한GCB(Non-Germinal B-cell-like) 미만성 거대 B-세포 림프종(DLBCL)미국
-
Relmada Therapeutics, Inc.빼는요로상피암 방광 | 비뇨기과 암 | 방광(요로상피, 이행세포) 암 | 방광(Urothelial, Transitional Cell) 암 표재성(비침습성)
infusions of Panitumumab에 대한 임상 시험
-
Memorial Sloan Kettering Cancer Center종료됨
-
Vanderbilt-Ingram Cancer Center모병HNSCC | SCC - 편평 세포 암종 | HNSCC, 후두, 인두 및 구강미국
-
Augusta University모병
-
Centro Hospitalar de Vila Nova de Gaia/Espinho,...모병
-
Kathmandu University School of Medical Sciences알려지지 않은